远大医药：全球创新RDC药物GPN02006研发迎来新突破

Core Insights - The company announced a significant breakthrough in the development of GPN02006, a global innovative radiolabeled drug conjugate (RDC) for diagnosing hepatocellular carcinoma (HCC) [1] - The clinical results of the investigator-initiated trial (IIT) were publicly presented at the Chengdu 2025 Future XDC New Drug Conference, marking a milestone in the company's oncology nuclear drug development efforts [1] - GPN02006 is expected to become the world's first RDC product targeting the GPC-3 marker for HCC diagnosis [1]